Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses

Journal of Virology

Volumn 86, Issue 15, 2012, Pages 7880-7886

  de Oya, Nereida Jiménez ^a,b   Escribano Romero, Estela ^a   Blázquez, Ana Belén ^a   Lorenzo, María ^a   Martín Acebes, Miguel A ^a,c   Blasco, Rafael ^a   Saiz, Juan Carlos ^a  

^a INIA   (Spain)

^b Division of Immunology   (Italy)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OPEN READING FRAME 2 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; HEPATITIS E VIRUS; IMMUNOGENICITY; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; SEQUENCE ANALYSIS; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; CELL LINE; CRICETINAE; GENE EXPRESSION; GLYCOSYLATION; HEPATITIS E VIRUS; HUMANS; MICE; RECOMBINANT PROTEINS; SWINE; VACCINIA VIRUS; VIRAL PROTEINS;

HEPATITIS E VIRUS; MUS; SUS; VACCINIA VIRUS;

EID: 84864381343     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00610-12     Document Type: Article

References (53)

1. Aggarwal R, Jameel S. 2008. Hepatitis E vaccine. Hepatol. Int. 2:308-315.
2. Baechlein C, et al. 2010. Prevalence of hepatitis E virus-specific antibodies in sera of German domestic pigs estimated by using different assays. Vet. Microbiol. 144:187-191.
3. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. 2010. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J. Med. Virol. 82:799-805.
4. Blasco R, Moss B. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
5. Carl M, et al. 1994. Expression of hepatitis E virus putative structural proteins in recombinant vaccinia viruses. Clin. Diagn. Lab. Immunol. 1:253-256.
6. Chandra V, Taneja S, Kalia M, Jameel S. 2008. Molecular biology and pathogenesis of hepatitis E virus. J. Biosci. 33:451-464.
7. Dalton HR, et al. 2008. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur. J. Gastroenterol. Hepatol. 20:784-790.
8. Daniel HD, Warier A, Abraham P, Sridharan G. 2004. Age-wise exposure rates to hepatitis E virus in a Southern Indian patient population without liver disease. Am. J. Trop. Med. Hyg. 71:675-678.
9. Elbein AD. 1987. Inhibitors of the biosynthesis and processing of Nlinked oligosaccharide chains. Annu. Rev. Biochem. 56:497-534.
10. Engelstad M, Howard ST, Smith GL. 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that form a part of the extracellular virus envelope. Virology 188:801-810.
11. Estes MK. 2007. Rotavirus, p 1747-1786. In Knipe DM et al. (ed), Fields virology. 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
12. Graff J, et al. 2008. Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J. Virol. 82:1185-1194.
13. Helenius A. 1994. How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol. Biol. Cell 5:253-265.
14. Herremans M, Bakker J, Duizer E, Vennema H, Koopmans MP. 2007. Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity. Clin. Vaccine Immunol. 14:562-568.
15. Huang F, et al. 2009. Experimental infection of Balb/c nude mice with hepatitis E virus. BMC Infect. Dis. 9:93.
16. Jacobs BL, et al. 2009. Vaccinia virus vaccines: past, present and future. Antiviral Res. 84:1-13.
17. Jameel S, Zafrullah M, Ozdener MH, Panda SK. 1996. Expression in animal cells and characterization of the hepatitis E virus structural proteins. J. Virol. 70:207-216.
18. Jiménez de Oya N, et al. 2011. Maternal transfer of antibodies to the offspring after mice immunization with insect larvae-derived recombinant hepatitis E virus ORF-2 proteins. Virus Res. 158:28-32.
19. Jiménez de Oya N, et al. 2009. Expression and immunoreactivities of hepatitis E virus genotype 3 open reading frame 2 (ORF-2) recombinant proteins expressed in insect cells. Food Environ. Virol. 1:77-84.
20. Jiménez de Oya N, et al. 2009. Serological immunoassay for detection of hepatitis E virus on the basis of genotype 3 open reading frame 2 recombinant proteins produced in Trichoplusia ni larvae. J. Clin. Microbiol. 47:3276-3282.
21. Johne R, et al. 2010. Detection of hepatitis E virus in faeces of wild rats using a nested broad spectrum RT-PCR. J. Gen. Virol. 91:750-758.
22. Kamar N, et al. 2008. Hepatitis E virus and chronic hepatitis in organtransplant recipients. N. Engl. J. Med. 358:811-817.
23. Kanai Y, et al. 2012. Hepatitis E virus in Norway rats (Rattus norvegicus) captured around a pig farm. BME Res. Notes 5:4.
24. Klausner RD, Donaldson JG, Lippincott-Schwartz J. 1992. Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol. 116:1071-1080.
25. Krawczynski K, Aggarwal R, Kamil S. 2000. Hepatitis E. Infect. Dis. Clin. North Am. 14:669-687.
26. Li TC, et al. 2008. Mice are not susceptible to hepatitis E virus infection. J. Vet. Med. Sci. 70:1359-1362.
27. Martín-Acebes MA, Blázquez AB, Jiménez de Oya N, Escribano-Romero E, Saiz JC. 2011. West Nile virus replication requires fatty acid synthesis but is independent of phosphatidylinositol-4-phosphate lipids. PLoS One 6:e24970. doi:10.1371/journal.pone.0024970.
28. Mast EE, Alter MJ, Holland PV, Purcell RH. 1998. Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Antibody Serum Panel Evaluation Group. Hepatology 27:857-861.
29. Meng XJ. 2010. Hepatitis E virus: animal reservoirs and zoonotic risk. Vet. Microbiol. 140:256-265.
30. Meng XJ. 2010. Recent advances in hepatitis E virus. J. Viral Hepat. 17: 153-161.
31. Meng XJ, et al. 2002. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and normal blood donors in the United States and other countries. J. Clin. Microbiol. 40:117-122.
32. Moss B. 2011. Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239:8-26.
33. Navaneethan U, Al Mohajer M, Shata MT. 2008. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 28:1190-1199.
34. Parkkinen JJ, et al. 1997. Polyamine-dependent alterations in the structure of microfilaments, Golgi apparatus, endoplasmic reticulum, and proteoglycan synthesis in BHK cells. J. Cell. Biochem. 66:165-174.
35. Pavio N, Meng XJ, Renou C. 2010. Zoonotic hepatitis E: animal reservoirs and emerging risks. Vet. Res. 41(6):46.
36. Purcell RH, Emerson SU. 2010. Hidden danger: the raw facts about hepatitis E virus. J. Infect. Dis. 202:819-821.
37. Purcell RH, et al. 2011. Hepatitis E virus in rats. Los Angeles, California, U. S. A. Emerg. Infect. Dis. 17:2216-2222.
38. Rehman S, Kapur N, Durgapal H, Panda KS. 2008. Subcellular localization of hepatitis E virus (HEV) replicase. Virology 370:77-92.
39. Reyes GR, et al. 1990. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247:1335-1339.
40. Schmelz M, et al. 1994. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J. Virol. 68:130-147.
41. Shrestha MP, et al. 2007. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 356:895-903.
42. Shukla P, et al. 2012. Adaptation of genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J. Virol. 86:5697-5707.
43. Shukla P, et al. 2011. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc. Natl. Acad. Sci. U. S. A. 108:2438-2443.
44. Surjit M, Jameel S, Lai SK. 2004. The ORF2 protein of hepatitis E virus binds to the 5' region of viral RNA. J. Virol. 78:320-328.
45. Surjit M, Jameel S, Lai SK. 2007. Cytoplasmic localization of the ORF2 protein of hepatitis E virus is dependent on its ability to undergo retrotranslocation from the endoplasmic reticulum. J. Virol. 81:3339-3345.
46. Takatsuki A, Arima K, Tamura G. 1971. Tunicamycin, a new antibiotic. I: isolation and characterization of tunicamycin. J. Antibiot. (Tokyo) 24:215-223.
47. Tam AW, et al. 1991. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185:120-131.
48. Tanaka T, Takahashi M, Kusano E, Okamoto H. 2007. Development and evaluation of an efficient cell-culture system for hepatitis E virus. J. Gen. Virol. 88:903-911.
49. Tanaka T, et al. 2009. Development and characterization of a genotype 4 hepatitis E virus cell culture system using HE-JF5/15F strain recovered from a fulminant hepatitis patient. J. Clin. Microbiol. 47:1906-1910.
50. Torresi J, Li F, Locarnini SA, Anderson DA. 1999. Only the nonglycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. J. Gen. Virol. 80:1185-1188.
51. Zafrullah M, Ozdener MH, Kumar R, Panda SK, Jameel S. 1999. Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. J. Virol. 73:4074-4082.
52. Zhang J, et al. 2009. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 27:1869-1874.
53. Zhu FC, et al. 2010. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial. Lancet 376:895-902.